Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.

[1]  A. Zarnani,et al.  Mutual Helper Effect in Copulsing of Dendritic Cells With 2 Antigens: A Novel Approach for Improvement of Dendritic-based Vaccine Efficacy Against Tumors and Infectious Diseases Simultaneously , 2009, Journal of immunotherapy.

[2]  Fang Wang,et al.  Multiepitope peptide‐loaded virus‐like particles as a vaccine against hepatitis B virus–related hepatocellular carcinoma , 2009, Hepatology.

[3]  P. Brossart,et al.  Vaccination strategies in patients with renal cell carcinoma , 2009, Cancer Immunology, Immunotherapy.

[4]  Songtao Yu,et al.  Induction of anti‐tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice , 2009, The Journal of pathology.

[5]  S. Senju,et al.  Multiple Antigen-targeted Immunotherapy With α-Galactosylceramide–loaded and Genetically Engineered Dendritic Cells Derived From Embryonic Stem Cells , 2009, Journal of immunotherapy.

[6]  L. Rollins,et al.  Targeting the Intratumoral Dendritic Cells by the Oncolytic Adenoviral Vaccine Expressing RANTES Elicits Potent Antitumor Immunity , 2009, Journal of immunotherapy.

[7]  N. Hollander,et al.  Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma1 , 2009, The Journal of Immunology.

[8]  M. Wilson,et al.  Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta‐analysis , 2009, International journal of cancer.

[9]  M. Mulcahy,et al.  Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. , 2008, World journal of gastroenterology.

[10]  L. Butterfield,et al.  α-Fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer , 2008 .

[11]  L. Butterfield,et al.  Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. , 2008, Expert opinion on biological therapy.

[12]  C. Sánchez-Torres,et al.  Differential CD4+ T‐cell memory responses induced by two subsets of human monocyte‐derived dendritic cells , 2007, Immunology.

[13]  K. Tsumoto,et al.  Human CD4+ central and effector memory T cells produce IL-21: effect on cytokine-driven proliferation of CD4+ T cell subsets. , 2007, International immunology.

[14]  Y. Hiasa,et al.  Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. , 2007, Journal of hepatology.

[15]  M. Erturk,et al.  Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study. , 2007, Journal of experimental & clinical cancer research : CR.

[16]  A. Ribas,et al.  Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer , 2007, Cancer Immunology, Immunotherapy.

[17]  K. Dou,et al.  alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. , 2007, Human immunology.

[18]  H. Zhang,et al.  Hepatitis B virus (HBV) antigen‐pulsed monocyte‐derived dendritic cells from HBV‐associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro , 2006, Clinical and experimental immunology.

[19]  K. Tsumoto,et al.  Human CD 4 1 central and effector memory T cells produce IL-21 : effect on cytokine-driven proliferation of CD 4 1 T cell subsets , 2007 .

[20]  P. Buchsel,et al.  Dendritic cells: emerging roles in tumor immunotherapy. , 2006, Clinical journal of oncology nursing.

[21]  S. Kaneko,et al.  Identification of α‐fetoprotein‐derived peptides recognized by cytotoxic T lymphocytes in HLA‐A24+ patients with hepatocellular carcinoma , 2006 .

[22]  S. Kaneko,et al.  Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. , 2006, International journal of cancer.

[23]  H. Ueno,et al.  Human Dendritic Cell Subsets for Vaccination , 2005, Journal of Clinical Immunology.

[24]  Roger Williams,et al.  Analysis of CD4+ T-Cell Responses to a Novel α-Fetoprotein-Derived Epitope in Hepatocellular Carcinoma Patients , 2005, Clinical Cancer Research.

[25]  P. Brossart,et al.  Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes , 2005, Cancer Gene Therapy.

[26]  W. Lau,et al.  The continuing challenge of hepatic cancer in Asia. , 2005, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[27]  Roger Williams,et al.  Analysis of CD 4 + T-Cell Responses to a Novel A-Fetoprotein-Derived Epitope in Hepatocellular Carcinoma Patients , 2005 .

[28]  H. Moll.  Antigen delivery by dendritic cells. , 2004, International journal of medical microbiology : IJMM.

[29]  R. Stripecke,et al.  Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. , 2004, Human gene therapy.

[30]  Roger Williams,et al.  α-Fetoprotein Impairs APC Function and Induces Their Apoptosis1 , 2004, The Journal of Immunology.

[31]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[32]  D. Curiel,et al.  Adenovirus-mediated gene delivery to dendritic cells. , 2004, Methods in molecular biology.

[33]  M. Del Vecchio,et al.  Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. , 2003, Human gene therapy.

[34]  R. Crystal,et al.  Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  D. Wei,et al.  [Immune responses of dendritic cells after loaded with cytotoxicity T lymphocyte epitope based peptide of human alpha-fetoprotein (hAFP)]. , 2002, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[36]  P. Hermonat,et al.  Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno‐associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells , 2002, European journal of immunology.

[37]  P. Hermonat,et al.  Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector , 2001, Cancer Gene Therapy.

[38]  L. Zitvogel,et al.  Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells1 , 2001, The Journal of Immunology.

[39]  J. Bubeník.  Genetically engineered dendritic cell-based cancer vaccines (review). , 2001, International journal of oncology.

[40]  M. Cotten,et al.  MHC class II presentation of endogenously expressed antigens by transfected dendritic cells , 2001, Gene Therapy.

[41]  N. Leung,et al.  Chronic hepatitis B virus infection in Asian countries , 2000, Journal of gastroenterology and hepatology.

[42]  J. Mayordomo,et al.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.